Study the Effect of Sofosbuvir Plus Daclatasvir on Lipid Metabolism and Apolipoprotein B in Chronic Egyptian Hepatitis C Virus Patients

Abstract

The study has demonstrated 100% negative PCR for HCV at the end of therapy indicating high efficacy of DAA in treatment of chronic hepatitis c virus patients. We found that Patients in the HCV Group had lower total cholesterol levels, LDL cholesterol, HDL cholesterol, triglyceride and apolipoprotien B than the uninfected control group. The study show significant increase in serum triglyceride (p value 0.001) and HDL cholesterol (P value 0.044) immediately after the end treatment. And non-significant increase in total cholesterol and LDL cholesterol after treatment than at base line indicating direct effect of HCV clearance on host lipid metabolism. The study also demonstrate significant increase in serum Apolipoprotien B (p value <0.001) with the end of treatment. These findings suggest that HCV infection by itself may be involved in the disturbance of serum lipoproteins/apolipoproteins Therefore, examining serum lipoproteins/apolipoproteins is beneficial for monitoring disturbed lipid metabolism induced by HCV.